Targeting chromatin-modifying enzymes is a promising strategy for cancer treatment. The antitumor effectivity of compounds inhibiting histone methyltransferases - mainly EZH2 - is currently being tested in phase I/II clinical trials, some of them showing positive results in hematological malignancies and solid tumors of specific mutational background. In this review, we aim at highlighting the recent advances in the field of histone methyltransferase inhibitors and describing the challenges that need to be addressed for their successful implementation in the clinics.

中文翻译：

---

在癌症中服用组蛋白甲基转移酶。

靶向染色质修饰酶是一种有前途的癌症治疗策略。目前正在I / II期临床试验中测试抑制组蛋白甲基转移酶（主要是EZH2）的化合物的抗肿瘤作用，其中一些在血液系统恶性肿瘤和特定突变背景的实体瘤中显示出积极的结果。在这篇综述中，我们旨在重点介绍组蛋白甲基转移酶抑制剂领域的最新进展，并描述在临床上成功实施组蛋白所需要解决的挑战。